---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-192006"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:35:53.667064+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022

## Summary
- CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.
- Goff receives $775K base salary, 70% target bonus, equity grants: $9M options, $5M PSUs, $2M RSUs.
- Goff also gets $250K relocation payment; equity awards vest over 3–4 years under Nasdaq inducement grant.
- Fouse's unvested equity continues to vest; she will not receive director equity awards in 2022.
- Former chair David Schenkein remains on board as director.

## SEC filing metadata
- accession: 0001193125-22-192006
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/d267394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-192006
- JSON: https://secwatch.observer/filing/0001193125-22-192006.json
- Plain text: https://secwatch.observer/filing/0001193125-22-192006.txt

## Key facts
- Executive change
  Jacqualyn A. Fouse changed role as Chair of the Board at AGIOS PHARMACEUTICALS, INC..
  - Action: assume the role of
  - Role: Chair of the Board
  source text: Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm
- Executive change
  Brian Goff was appointed as Chief Executive Officer at AGIOS PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board appointed Brian Goff as the Company’s Chief Executive Officer and as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.